Ceftolozane-tazobactam: When, how and why using it?
Ceftolozane-tazobactam is currently the most active antipseudomonal agent, including multidrug-resistant extensively drug-resistant strains. Tazobactam provides additional activity against many extended-spectrum beta-lactamases Enterobacterales. Ceftolozane-tazobactam is formally approved for compli...
Gespeichert in:
| Veröffentlicht in: | Revista española de quimioterapia 2021-09, Vol.34 Suppl 1 (Suppl 1), p.35-37 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 37 |
|---|---|
| container_issue | Suppl 1 |
| container_start_page | 35 |
| container_title | Revista española de quimioterapia |
| container_volume | 34 Suppl 1 |
| creator | López Montesinos, I Montero, M Sorlí, L Horcajada, J P |
| description | Ceftolozane-tazobactam is currently the most active antipseudomonal agent, including multidrug-resistant extensively drug-resistant strains. Tazobactam provides additional activity against many extended-spectrum beta-lactamases Enterobacterales. Ceftolozane-tazobactam is formally approved for complicated urinary tract infection, complicated intra-abdominal infection, and hospital-acquired and ventilator-associated bacterial pneumonia. The clinical and microbiological success is over 70-80% in many series. However, resistant mutants to ceftolozane-tazobactam have been already described. Combination therapies with colistin or meropenem could be among the strategies to avoid the resistance emergence. |
| doi_str_mv | 10.37201/req/s01.10.2021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8682999</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2578774763</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-e44aed2c0e5b5e1d2003cda829d8bef98e96604f4cef2d48f3ff03e6fff59b153</originalsourceid><addsrcrecordid>eNpVkL1PwzAQxS0EoqWwM6GMDKT4K4nNAEIVX1IlFhCj5STnJiiJ2zihav96XFoqmE569-7d3Q-hc4LHLKGYXLewuHaYjL1AMSUHaEikEKGMiDhEQ6_wkHEqB-jEuU-MOeOSHKMB45EUnNIhYhMwna3sWjcQdnptU511ur4JPgporoLCLgPd5MGyWAW9K5tZUHZ3p-jI6MrB2a6O0Pvjw9vkOZy-Pr1M7qdhxmTchcC5hpxmGKI0ApJTjFmWa0FlLlIwUoCMY8wNz8DQnAvDjMEMYmNMJFMSsRG63ebO-7SGPIOma3Wl5m1Z63alrC7V_05TFmpmv5SI_RIpfcDlLqC1ix5cp-rSZVBV_lnbO0WjRCQJT2LmrXhrzVrrXAtmv4Zg9cNaedbKs94IG9Z-5OLvefuBX7jsG9Z3fEc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2578774763</pqid></control><display><type>article</type><title>Ceftolozane-tazobactam: When, how and why using it?</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed</source><source>EZB Electronic Journals Library</source><creator>López Montesinos, I ; Montero, M ; Sorlí, L ; Horcajada, J P</creator><creatorcontrib>López Montesinos, I ; Montero, M ; Sorlí, L ; Horcajada, J P ; Department of Infectious Diseases, Hospital del Mar-IMIM. Barcelona</creatorcontrib><description>Ceftolozane-tazobactam is currently the most active antipseudomonal agent, including multidrug-resistant extensively drug-resistant strains. Tazobactam provides additional activity against many extended-spectrum beta-lactamases Enterobacterales. Ceftolozane-tazobactam is formally approved for complicated urinary tract infection, complicated intra-abdominal infection, and hospital-acquired and ventilator-associated bacterial pneumonia. The clinical and microbiological success is over 70-80% in many series. However, resistant mutants to ceftolozane-tazobactam have been already described. Combination therapies with colistin or meropenem could be among the strategies to avoid the resistance emergence.</description><identifier>ISSN: 0214-3429</identifier><identifier>EISSN: 1988-9518</identifier><identifier>DOI: 10.37201/req/s01.10.2021</identifier><identifier>PMID: 34598422</identifier><language>eng</language><publisher>Spain: Sociedad Española de Quimioterapia</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Cephalosporins - therapeutic use ; Colistin ; Humans ; Intraabdominal Infections - drug therapy ; Microbial Sensitivity Tests ; Pseudomonas aeruginosa ; Pseudomonas Infections - drug therapy ; Tazobactam - therapeutic use ; Update on Antimicrobial Pharmacotherapy</subject><ispartof>Revista española de quimioterapia, 2021-09, Vol.34 Suppl 1 (Suppl 1), p.35-37</ispartof><rights>The Author 2021 2021</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-e44aed2c0e5b5e1d2003cda829d8bef98e96604f4cef2d48f3ff03e6fff59b153</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8682999/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8682999/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34598422$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>López Montesinos, I</creatorcontrib><creatorcontrib>Montero, M</creatorcontrib><creatorcontrib>Sorlí, L</creatorcontrib><creatorcontrib>Horcajada, J P</creatorcontrib><creatorcontrib>Department of Infectious Diseases, Hospital del Mar-IMIM. Barcelona</creatorcontrib><title>Ceftolozane-tazobactam: When, how and why using it?</title><title>Revista española de quimioterapia</title><addtitle>Rev Esp Quimioter</addtitle><description>Ceftolozane-tazobactam is currently the most active antipseudomonal agent, including multidrug-resistant extensively drug-resistant strains. Tazobactam provides additional activity against many extended-spectrum beta-lactamases Enterobacterales. Ceftolozane-tazobactam is formally approved for complicated urinary tract infection, complicated intra-abdominal infection, and hospital-acquired and ventilator-associated bacterial pneumonia. The clinical and microbiological success is over 70-80% in many series. However, resistant mutants to ceftolozane-tazobactam have been already described. Combination therapies with colistin or meropenem could be among the strategies to avoid the resistance emergence.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Cephalosporins - therapeutic use</subject><subject>Colistin</subject><subject>Humans</subject><subject>Intraabdominal Infections - drug therapy</subject><subject>Microbial Sensitivity Tests</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Tazobactam - therapeutic use</subject><subject>Update on Antimicrobial Pharmacotherapy</subject><issn>0214-3429</issn><issn>1988-9518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkL1PwzAQxS0EoqWwM6GMDKT4K4nNAEIVX1IlFhCj5STnJiiJ2zihav96XFoqmE569-7d3Q-hc4LHLKGYXLewuHaYjL1AMSUHaEikEKGMiDhEQ6_wkHEqB-jEuU-MOeOSHKMB45EUnNIhYhMwna3sWjcQdnptU511ur4JPgporoLCLgPd5MGyWAW9K5tZUHZ3p-jI6MrB2a6O0Pvjw9vkOZy-Pr1M7qdhxmTchcC5hpxmGKI0ApJTjFmWa0FlLlIwUoCMY8wNz8DQnAvDjMEMYmNMJFMSsRG63ebO-7SGPIOma3Wl5m1Z63alrC7V_05TFmpmv5SI_RIpfcDlLqC1ix5cp-rSZVBV_lnbO0WjRCQJT2LmrXhrzVrrXAtmv4Zg9cNaedbKs94IG9Z-5OLvefuBX7jsG9Z3fEc</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>López Montesinos, I</creator><creator>Montero, M</creator><creator>Sorlí, L</creator><creator>Horcajada, J P</creator><general>Sociedad Española de Quimioterapia</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210901</creationdate><title>Ceftolozane-tazobactam: When, how and why using it?</title><author>López Montesinos, I ; Montero, M ; Sorlí, L ; Horcajada, J P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-e44aed2c0e5b5e1d2003cda829d8bef98e96604f4cef2d48f3ff03e6fff59b153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Cephalosporins - therapeutic use</topic><topic>Colistin</topic><topic>Humans</topic><topic>Intraabdominal Infections - drug therapy</topic><topic>Microbial Sensitivity Tests</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Tazobactam - therapeutic use</topic><topic>Update on Antimicrobial Pharmacotherapy</topic><toplevel>online_resources</toplevel><creatorcontrib>López Montesinos, I</creatorcontrib><creatorcontrib>Montero, M</creatorcontrib><creatorcontrib>Sorlí, L</creatorcontrib><creatorcontrib>Horcajada, J P</creatorcontrib><creatorcontrib>Department of Infectious Diseases, Hospital del Mar-IMIM. Barcelona</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Revista española de quimioterapia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>López Montesinos, I</au><au>Montero, M</au><au>Sorlí, L</au><au>Horcajada, J P</au><aucorp>Department of Infectious Diseases, Hospital del Mar-IMIM. Barcelona</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ceftolozane-tazobactam: When, how and why using it?</atitle><jtitle>Revista española de quimioterapia</jtitle><addtitle>Rev Esp Quimioter</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>34 Suppl 1</volume><issue>Suppl 1</issue><spage>35</spage><epage>37</epage><pages>35-37</pages><issn>0214-3429</issn><eissn>1988-9518</eissn><abstract>Ceftolozane-tazobactam is currently the most active antipseudomonal agent, including multidrug-resistant extensively drug-resistant strains. Tazobactam provides additional activity against many extended-spectrum beta-lactamases Enterobacterales. Ceftolozane-tazobactam is formally approved for complicated urinary tract infection, complicated intra-abdominal infection, and hospital-acquired and ventilator-associated bacterial pneumonia. The clinical and microbiological success is over 70-80% in many series. However, resistant mutants to ceftolozane-tazobactam have been already described. Combination therapies with colistin or meropenem could be among the strategies to avoid the resistance emergence.</abstract><cop>Spain</cop><pub>Sociedad Española de Quimioterapia</pub><pmid>34598422</pmid><doi>10.37201/req/s01.10.2021</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0214-3429 |
| ispartof | Revista española de quimioterapia, 2021-09, Vol.34 Suppl 1 (Suppl 1), p.35-37 |
| issn | 0214-3429 1988-9518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8682999 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed; EZB Electronic Journals Library |
| subjects | Anti-Bacterial Agents - therapeutic use Cephalosporins - therapeutic use Colistin Humans Intraabdominal Infections - drug therapy Microbial Sensitivity Tests Pseudomonas aeruginosa Pseudomonas Infections - drug therapy Tazobactam - therapeutic use Update on Antimicrobial Pharmacotherapy |
| title | Ceftolozane-tazobactam: When, how and why using it? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T14%3A55%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ceftolozane-tazobactam:%20When,%20how%20and%20why%20using%20it?&rft.jtitle=Revista%20espa%C3%B1ola%20de%20quimioterapia&rft.au=L%C3%B3pez%20Montesinos,%20I&rft.aucorp=Department%20of%20Infectious%20Diseases,%20Hospital%20del%20Mar-IMIM.%20Barcelona&rft.date=2021-09-01&rft.volume=34%20Suppl%201&rft.issue=Suppl%201&rft.spage=35&rft.epage=37&rft.pages=35-37&rft.issn=0214-3429&rft.eissn=1988-9518&rft_id=info:doi/10.37201/req/s01.10.2021&rft_dat=%3Cproquest_pubme%3E2578774763%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2578774763&rft_id=info:pmid/34598422&rfr_iscdi=true |